Actively Recruiting
R-CMOP in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma
Led by Institute of Hematology & Blood Diseases Hospital, China · Updated on 2025-05-14
108
Participants Needed
1
Research Sites
165 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a prospective clinical study to evaluate the safety and efficacy of R-CMOP in patients with newly diagnosed diffuse large B-cell lymphoma
CONDITIONS
Official Title
R-CMOP in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Newly diagnosed, untreated diffuse large B-cell lymphoma confirmed by tissue analysis
- At least one measurable lymphoma lesion larger than 1.5 cm with positive PET-CT
- Ann Arbor stage II to IV disease
- ECOG performance status of 0 to 2
- Expected survival of at least 3 months
- Blood counts meeting specific minimum levels, adjusted if bone marrow is involved
- Liver enzymes and kidney function within defined safe limits
- Coagulation function within normal limits
- Female patients of childbearing age must have a negative pregnancy test within one week before enrollment and agree to use effective contraception during and for 12 months after treatment
- Able to understand and agree to study procedures and sign informed consent
You will not qualify if you...
- Certain lymphoma subtypes including primary central nervous system DLBCL and others listed
- Transformed indolent lymphoma
- Active central nervous system lymphoma involvement
- History of stem cell transplantation
- Prior anti-lymphoma treatment except short-term or low-dose corticosteroids
- Use of anticancer herbal or proprietary Chinese medicines within 14 days before first dose
- Allergy or contraindication to study drugs or their components
- Participation in other intervention clinical trials within 4 weeks prior to first dose
- Active bacterial or viral infections requiring systemic treatment
- History of immunodeficiency or positive HIV
- Active hepatitis B or C infection
- Syphilis infection
- Medical conditions or substance abuse that interfere with study participation or safety
- Interstitial lung disease requiring treatment
- Severe cardiovascular disease including certain arrhythmias, QT prolongation, recent serious cardiac events, heart failure, or uncontrolled hypertension
- History of other cancers within 2 years except certain treated skin or localized cancers
- Psychological or spiritual issues that may hinder study adherence
- Pregnant or breastfeeding women
- Any other condition deemed unsuitable by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Institute of Hematology & Blood Disease Hospital
Tianjin, Tianjin Municipality, China, 300020
Actively Recruiting
Research Team
W
Wei Liu
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here